Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks, has announced its participation in the Inaugural Guggenheim Securities Healthcare Innovation Conference. The event will take place at the InterContinental Boston from November 11-13, 2024.
The company will participate in a fireside chat on Wednesday, November 13, at 9:30 a.m. ET. A live audio webcast will be available on the Investors section of the Pharvaris website, with the replay accessible for 30 days after the presentation.
Pharvaris (Nasdaq: PHVS), una compagnia biofarmaceutica in fase avanzata focalizzata sullo sviluppo di antagonisti orali del recettore della bradikinin B2 per gli attacchi di angioedema ereditario (HAE), ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim Securities. L'evento si svolgerà presso l'InterContinental di Boston dal 11 al 13 novembre 2024.
L'azienda parteciperà a una chat informale mercoledì 13 novembre, alle 9:30 ET. Un webcast audio in diretta sarà disponibile nella sezione Investitori del sito web di Pharvaris, con la registrazione accessibile per 30 giorni dopo la presentazione.
Pharvaris (Nasdaq: PHVS), una empresa biofarmacéutica en etapa avanzada centrada en el desarrollo de antagonistas orales del receptor de bradiquina B2 para los ataques de angioedema hereditario (HAE), ha anunciado su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim Securities. El evento se llevará a cabo en el InterContinental de Boston del 11 al 13 de noviembre de 2024.
La empresa participará en una charla informal el miércoles 13 de noviembre a las 9:30 a.m. ET. Una transmisión en vivo de audio estará disponible en la sección de Inversores del sitio web de Pharvaris, con la repetición accesible durante 30 días después de la presentación.
Pharvaris (Nasdaq: PHVS)는 유전성 혈관 부종(HAE) 발작을 위한 경구 브라디키닌 B2 수용체 길항제를 개발하는 데 중점을 둔 임상 후 바이오 제약 회사입니다. 이 회사는 구겐하임 증권 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 11월 11일부터 13일까지 보스턴의 인터컨티넨탈 호텔에서 열릴 예정입니다.
회사는 11월 13일 수요일 오전 9:30(ET)에 열리는 파이어사이드 챗에 참석할 것입니다. 생중계 오디오 웹캐스트는 Pharvaris 웹사이트의 투자자 섹션에서 제공되며, 프레젠테이션 후 30일 동안 다시 볼 수 있습니다.
Pharvaris (Nasdaq: PHVS), une entreprise biopharmaceutique en phase avancée spécialisée dans le développement d'antagonistes oraux du récepteur de la bradykinine B2 pour les attaques d'œdème angioneurotique héréditaire (HAE), a annoncé sa participation à la Conférence Inaugurale sur l'Innovation Sanitaire de Guggenheim Securities. L'événement se déroulera à l'InterContinental de Boston du 11 au 13 novembre 2024.
L'entreprise participera à une discussion informelle le mercredi 13 novembre à 9h30 ET. Un webinaire audio en direct sera disponible dans la section Investisseurs du site web de Pharvaris, et la rediffusion sera accessible pendant 30 jours après la présentation.
Pharvaris (Nasdaq: PHVS), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf die Entwicklung von oralen Bradykinin-B2-Rezeptorantagonisten zur Behandlung von hereditärem Angioödem (HAE)-Anfällen konzentriert, hat seine Teilnahme an der Ersten Guggenheim Securities Healthcare Innovation Conference angekündigt. Die Veranstaltung findet vom 11. bis 13. November 2024 im InterContinental Boston statt.
Das Unternehmen wird am Mittwoch, dem 13. November, um 9:30 Uhr ET an einem Fireside-Chat teilnehmen. Ein Live-Audio-Webcast wird im Anlegerbereich der Pharvaris-Website verfügbar sein, und die Aufzeichnung ist 30 Tage nach der Präsentation abrufbar.
- None.
- None.
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows:
| Format: | Fireside Chat | |
| Date, time: | Wednesday, November 13, 9:30 a.m. ET | |
| Webcast Link | ||
A live audio webcast will also be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replay will be available on Pharvaris’ website for 30 days following the presentation.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE by year-end 2024. For more information, visit https://pharvaris.com/.
FAQ
When is Pharvaris (PHVS) presenting at the Guggenheim Healthcare Innovation Conference 2024?
Where can I watch Pharvaris (PHVS) Guggenheim Conference presentation?
What type of treatments is Pharvaris (PHVS) developing?
